HIV-1 Env vaccine comprised of electroporated DNA and protein co-administered with Talabostat
| Autor: | Lindsey Galmin, Phillip D. Markham, Ruxandra Draghia-Akli, Susana Restrepo, John J. Suschak, Deborah T. Weiss, Ranajit Pal, Brad Lewis, Lauren Hudacik, Nazneen Aziz, Anthony D. Cristillo |
|---|---|
| Rok vydání: | 2008 |
| Předmět: |
Cellular immunity
Biophysics HIV Envelope Protein gp120 Biochemistry law.invention Mice Th2 Cells law Vaccines DNA Animals Molecular Biology AIDS Vaccines Mice Inbred BALB C biology Immunogenicity Antibody titer virus diseases Dipeptides Cell Biology Th1 Cells Boronic Acids Virology Recombinant Proteins CTL Electroporation Antibody Formation DNA Viral Humoral immunity Immunology HIV-1 biology.protein Recombinant DNA Cytokines Female Antibody CD8 |
| Zdroj: | Biochemical and Biophysical Research Communications. 370:22-26 |
| ISSN: | 0006-291X |
| Popis: | Selection of potent yet low reactogenic adjuvants for protein immunization is important for HIV-1 vaccine development. Immunogenicity of electroporated DNA (HIV env) and recombinant gp120, administered with either QS-21 or the orally administered immunomodulator, Talabostat, was evaluated in BALB/c mice. Electroporation of low dose DNA elicited Th1 cytokines and anti-envelope antibodies. Immunization with gp120 protein alone with or without Talabostat elicited lower Th1 and Th2 cytokine levels but comparable anti-gp120 antibodies to QS-21-formulated protein. Boosting of DNA-primed mice with gp120/Talabostat induced similar anti-gp120 antibody titers and slightly higher levels of Th1 and Th2 cytokines relative to QS-21-formulated protein. Induction of CD8(+) and CD4(+) T cells and functional CTL activity was noted. These results highlight the potential use of orally administered Talabostat for efficient protein boosting of antibody and T-cell responses primed by DNA. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|
Full Text from ScienceDirect